Qualigen Therapeutics Faces Nasdaq Delisting Notification

Qualigen Therapeutics ( (QLGN) ) has issued an announcement.

On May 19, 2025, Qualigen Therapeutics, Inc. received a deficiency notification from Nasdaq due to its failure to timely file its Quarterly Report on Form 10-Q for the period ending March 31, 2025. This notification may lead to the company’s securities being delisted from Nasdaq, as it represents an additional deficiency under Nasdaq Listing Rule 5250(c)(1). The company plans to present its compliance plan at a scheduled hearing to address this issue, although there is no assurance of an extension or regaining compliance.

Spark’s Take on QLGN Stock

According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.

Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.

To see Spark’s full report on QLGN stock, click here.

More about Qualigen Therapeutics

Average Trading Volume: 60,063

Technical Sentiment Signal: Sell

Current Market Cap: $2.85M

Learn more about QLGN stock on TipRanks’ Stock Analysis page.